Results 1 to 10 of about 2,048,259 (212)

When Ring Sideroblasts on Bone Marrow Smears Are Inconsistent with the Diagnosis of Myelodysplastic Neoplasms [PDF]

Diagnostics, 2022
Ring sideroblasts are commonly seen in myelodysplastic neoplasms and are a key condition for identifying distinct entities of myelodysplastic neoplasms according to the WHO classification.
Sandrine Girard, Franck Genevieve, Emmanuelle Rault, Odile Fenneteau, Jean-François Lesesve   +4 more
doaj   +6 more sources

Real-World Diagnostic Testing Patterns for Assessment of Ring Sideroblasts and SF3B1 Mutations in Patients With Newly Diagnosed Lower-Risk Myelodysplastic Syndromes [PDF]

International Journal of Laboratory Hematology, 2021
The presence of ring sideroblasts (RS) and mutation of the SF3B1 gene are diagnostic of lower‐risk (LR) myelodysplastic syndromes (MDS) and are correlated with favorable outcomes.
Kathy Foucar, Tracy I George, Daniel A Pollyea   +2 more
exaly   +4 more sources

Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts. [PDF]

Cancer Res, 2023
Ring sideroblast isolation combined with state-of-the-art multiomics identifies survival mechanisms underlying SF3B1-mutant erythropoiesis and establishes an active role for erythroid differentiation and ring sideroblasts themselves in SF3B1-mutant ...
Moura PL, Mortera-Blanco T, Hofman IJ, Todisco G, Kretzschmar WW, Björklund AC, Creignou M, Hagemann-Jensen M, Ziegenhain C, Cabrerizo Granados D, Barbosa I, Walldin G, Jansson M, Ashley N, Mead AJ, Lundin V, Dimitriou M, Yoshizato T, Woll PS, Ogawa S, Sandberg R, Jacobsen SEW, Hellström-Lindberg E.   +22 more
europepmc   +4 more sources

Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging study [PDF]

Therapeutic Advances in Hematology
Background: Patients with lower-risk myelodysplastic syndromes (MDS) may experience anemia and a high transfusion burden, alongside a risk of progression to acute myeloid leukemia.
Chunkang Chang, Takahiro Suzuki, Yang Liang, Hongyan Tong, Kensuke Usuki, Qifa Liu, Yu Wu, Tomoaki Fujisaki, Bing Han, Ruibin Huang, Yasuyoshi Morita, Miao Miao, Yasuhiro Nakashima, Yu (Olivia) Tian, Jie Pu, Dimple Aggarwal, Veronika Pozharskaya, Wenhui Shi, Zhijian Xiao, Kinuko Mitani   +19 more
doaj   +3 more sources

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients [PDF]

Blood Cancer Journal, 2022
The current World Health Organization (WHO) classification of myeloid malignancies includes myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) as a distinct entity.
Abhishek A. Mangaonkar, Terra L. Lasho, Rhett P. Ketterling, Kaaren K. Reichard, Naseema Gangat, Aref Al-Kali, Kebede H. Begna, Animesh Pardanani, Najla H. Al Ali, Chetasi Talati, David Sallman, Eric Padron, Mrinal M. Patnaik, Ayalew Tefferi, Rami Komrokji   +14 more
doaj   +3 more sources

Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome [PDF]

Leukemia Research Reports, 2018
We describe a patient with MDS/MPN with ring sideroblasts and thrombocytosis who had deletions of long arm of chromosome 5 (5q-) and chromosome 20 (20q-).
Ahmed Alshaban, Osvaldo Padilla, Alexander Philipovskiy, Javier Corral, Meghan McAlice, Sumit Gaur   +5 more
doaj   +4 more sources

Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts. [PDF]

Clin Cancer Res, 2023
Purpose: Ring sideroblasts (RS) define the low-risk myelodysplastic neoplasm (MDS) subgroup with RS but may also reflect erythroid dysplasia in higher risk myeloid neoplasm.
Todisco G, Creignou M, Bernard E, Björklund AC, Moura PL, Tesi B, Mortera-Blanco T, Sander B, Jansson M, Walldin G, Barbosa I, Reinsbach SE, Hofman IJ, Nilsson C, Yoshizato T, Dimitriou M, Chang D, Chang D, Olafsdottir S, Venckute Larsson S, Tobiasson M, Malcovati L, Woll P, Jacobsen SEW, Papaemmanuil E, Hellström-Lindberg E.   +25 more
europepmc   +2 more sources

Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts. [PDF]

Leukemia, 2023
TO THE EDITOR: Two new proposals for the classification of myeloid malignancies have been presented: the 5th edition of the WHO Classification (WHO 2022 [1]) and the International Consensus Classification (ICC [2]).
Huber S, Haferlach T, Meggendorfer M, Hutter S, Hoermann G, Summerer I, Fuhrmann I, Baer C, Kern W, Haferlach C.   +9 more
europepmc   +2 more sources

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. [PDF]

Leukemia, 2023
TO THE EDITOR: Myelodysplastic syndromes (MDS) are disorders of hematopoietic stem cells characterized by ineffective hematopoiesis, commonly leading to anemia [1].
Platzbecker U, Santini V, Komrokji RS, Zeidan AM, Garcia-Manero G, Buckstein R, Miteva D, Keeperman K, Holot N, Nadal JA, Lai Y, Vodala S, Rosettani B, Giuseppi AC, Yucel A, Fenaux P.   +15 more
europepmc   +2 more sources

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. [PDF]

Leukemia, 2022
Myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a myeloid disorder with myelodysplastic and myeloproliferative features [1, 2].
Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, Díez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, Verma A.   +19 more
europepmc   +2 more sources